2, 3-dimercaptosuccinic acid-modified iron oxide clusters for magnetic resonance imaging.
2, 3-dimercaptosuccinic acid-modified iron oxide clusters for magnetic resonance imaging.
复制标题
DOI：
10.1002/jps.24209
复制
发表时间：
2014-12
影响因子：
3.8
通讯作者：
F. Xiong;Caiyun Yan;Jilai Tian;Kun-kun Geng;Ziyi Zhu;Lina Song;Yu Zhang;Matthew Mulvale;
中科院分区：
文献类型：
--
作者：
F. Xiong;Caiyun Yan;Jilai Tian;Kun-kun Geng;Ziyi Zhu;Lina Song;Yu Zhang;Matthew Mulvale;
在过去的十年中，各种磁性纳米材料已被开发作为磁共振成像（MRI）造影剂；临床应用遇到的最大挑战是稳定性不够。本文开发了一种2, 3-二巯基丁二酸修饰氧化铁（γ-Fe2O3@DMSA）纳米颗粒的冻干方法，同时克服了两个缺点：这些包括稳定性不足和磁响应低。冻干后形成尺寸为156.7±15.3 nm的γ-Fe2O3@DMSA簇，冻干粉(γ-Fe2O3@DMSA-LP)的稳定性提高至3年以上。还发现再水化的γ-Fe2O3@DMSA-LP可以被RAW264.7细胞大量摄取。体内药代动力学和生物分布研究结果表明，γ-Fe2O3@DMSA-LP是一种有前途的肝脏靶向材料。此外，与知名产品Feridex(®)相比，它还表现出更高的MRI效率和更长的肝脏成像时间。此外，血管刺激和长期毒性实验的结果表明γ-Fe2O3@DMSA-LP可以是体内无毒、生物相容性造影剂。因此，所提出的γ-Fe2O3@DMSA-LP可以作为临床肝病的潜在MRI造影剂。
Over the last decade, various magnetic nanomaterials have been developed as magnetic resonance imaging (MRI) contrast agents; the greatest challenges encountered for clinical application have been insufficient stability. In this paper, a lyophilization method for 2, 3-dimercaptosuccinic acid-modified iron oxide (γ-Fe2 O3 @DMSA) nanoparticles was developed to simultaneously overcome two disadvantages; these include insufficient stability and low-magnetic response. After lyophilization, the clusters of γ-Fe2 O3 @DMSA with the size of 156.7 ± 15.3 nm were formed, and the stability of the lyophilized powder (γ-Fe2 O3 @DMSA-LP) increased up to over 3 years. It was also found that rehydrated γ-Fe2 O3 @DMSA-LP could be ingested by RAW264.7 cells in very large quantities. Results of pharmacokinetics and biodistribution studies in vivo indicated that γ-Fe2 O3 @DMSA-LP is a promising liver-targeted material. Furthermore, it also exhibited higher MRI efficiency and longer imaging time in the liver than the well-known product Feridex(®) . Moreover, results of vascular irritation and long-term toxicity experiments demonstrated γ-Fe2 O3 @DMSA-LP could be a nontoxic, biocompatible contrast agent in vivo. Therefore, the proposed γ-Fe2 O3 @DMSA-LP can be used as a potential MRI contrast agent in clinic for hepatic diseases.